- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
